The Europe Fecal Immunochemical Test (FIT) Market was valued at US$ 1.4 Bn in 2023 and is projected to expand at a CAGR of 7.1% from 2024 to 2034, reaching more than US$ 2.9 Bn by the end of 2034, according to the latest market analysis. The market is witnessing significant growth due to the increasing prevalence of colorectal cancer (CRC), rising awareness regarding early cancer detection, supportive government screening initiatives, and continuous advancements in diagnostic technologies.

Fecal Immunochemical Tests (FIT) have emerged as one of the most preferred screening methods for colorectal cancer owing to their non-invasive nature, superior sensitivity, and ability to detect occult blood in stool samples without dietary restrictions. As healthcare systems across Europe focus on preventive care and cost-effective screening programs, the adoption of FIT-based testing continues to accelerate.

Analyst Viewpoint

The Europe FIT market is poised for sustained growth as healthcare authorities intensify efforts to improve colorectal cancer screening rates. Growing incidence of CRC associated with aging populations, sedentary lifestyles, obesity, smoking, and dietary factors is increasing demand for reliable screening solutions.

Analysts note that FIT has become the preferred screening method across many European countries due to its convenience, patient acceptance, and clinical effectiveness. The dominance of kits and reagents reflects their critical role in ensuring accurate results while minimizing testing errors. Additionally, hospitals and diagnostic centers continue to account for a substantial share of testing volumes due to their established infrastructure and skilled healthcare professionals.

The homecare segment is expected to witness notable growth during the forecast period, supported by increasing demand for accessible and patient-friendly diagnostic solutions.

Europe Fecal Immunochemical Test (FIT) Market Overview

Early detection remains one of the most effective approaches to reducing mortality associated with colorectal cancer. FIT enables healthcare providers to identify hidden blood in stool samples with high specificity and sensitivity, facilitating timely diagnosis and treatment.

Unlike traditional guaiac fecal occult blood tests (gFOBT), FIT does not require dietary restrictions, making it more convenient for patients and improving screening compliance rates.

European healthcare guidelines increasingly recommend FIT as the primary screening tool for colorectal cancer. The National Institute for Health and Care Excellence (NICE) advocates FIT screening in primary care settings, particularly for symptomatic patients, enabling more efficient utilization of colonoscopy resources while improving patient outcomes.

Europe accounted for approximately 34.3% of the global FIT market in 2023, highlighting the region's leadership in colorectal cancer screening initiatives. Strategic investments, funding activities, and expansion initiatives by major diagnostics companies are further strengthening market competitiveness and accelerating technological innovation.

Rising Awareness of Early Cancer Detection Driving Market Growth

Growing public awareness regarding the benefits of early colorectal cancer detection is emerging as a key factor propelling market expansion.

Colorectal cancer remains one of the most prevalent cancers across Europe. In Ireland alone, more than 2,270 new CRC cases and 910 deaths were reported in a single year, emphasizing the importance of widespread screening initiatives.

Healthcare studies indicate that while a majority of individuals prefer early diagnosis, many hesitate to undergo colonoscopy due to concerns about discomfort and invasiveness. FIT addresses this challenge by providing a simple, convenient, and non-invasive alternative that aligns with patient preferences.

Increasing educational campaigns, awareness programs, and government-sponsored screening initiatives are encouraging greater participation in CRC screening programs, thereby supporting demand for FIT products throughout Europe.

The adoption of FIT as a primary screening tool not only improves patient outcomes but also reduces healthcare costs by minimizing unnecessary colonoscopy procedures and facilitating earlier intervention.

Kits & Reagents Segment Leads Product Landscape

Based on product type, the Europe FIT market is segmented into:

• Kits & Reagents
• Analyzers
• Others

Among these, kits & reagents accounted for the largest market share in 2023.

These products contain essential components such as test strips, reagents, and buffer solutions required for accurate sample analysis. Their role in improving test reliability and reducing diagnostic errors makes them indispensable in colorectal cancer screening programs.

According to European healthcare statistics, individuals aged 65 years and above account for a significant proportion of new cancer diagnoses. As aging populations continue to grow across Europe, demand for dependable FIT kits and reagents is expected to increase substantially.

Manufacturers are focusing on enhancing test accuracy, ease of use, and scalability to meet rising screening demands, creating lucrative opportunities within this segment.

Hospitals & Diagnostic Centers Continue to Dominate End-user Segment

By end-user, the market is categorized into:

• Hospitals & Diagnostics Centers
• Specialty Clinics
• Homecare Settings
• Research Institutes

Hospitals and diagnostic centers currently hold the leading market share due to their advanced laboratory infrastructure, skilled personnel, and established reimbursement systems.

These facilities offer comprehensive diagnostic services and rapid testing capabilities, making them the preferred choice for colorectal cancer screening and follow-up care.

However, homecare settings are expected to experience the fastest growth during the forecast period. Increased adoption of at-home testing kits is improving screening accessibility among elderly individuals, patients with mobility limitations, and populations residing in remote areas.

The growing popularity of home-based healthcare solutions is expected to complement institutional screening efforts and expand overall market penetration.

Germany Emerges as the Leading Country Market

Germany currently represents the largest market for fecal immunochemical testing in Europe.

Colorectal cancer remains among the most commonly diagnosed cancers in the country and continues to be a major cause of cancer-related mortality. Strong government support, established screening frameworks, clinical guidelines, and healthcare quality initiatives have contributed significantly to market growth.

National screening programs across Germany and other European countries are driving higher participation rates and promoting routine colorectal cancer testing.

Furthermore, initiatives such as the European Commission’s Beating Cancer Plan aim to expand screening coverage among eligible populations, standardize diagnostic pathways, and improve public awareness regarding preventive healthcare.

These efforts are expected to create long-term opportunities for market participants while strengthening colorectal cancer prevention strategies across the region.

Competitive Landscape

The Europe fecal immunochemical test (FIT) market remains highly competitive, with leading companies focusing on product innovation, technological advancements, strategic partnerships, and expansion initiatives.

Key players operating in the market include:

• Abbott Rapid Diagnostics
• Una Health
• Alpha Laboratories Ltd
• BIOHIT HealthCare Ltd
• Sysmex UK
• MAST Group Ltd
• Epigenomics AG
• Alfresa Pharma Corporation
• Aidian Oy
• Minaris Medical
• Immundiagnostik AG
• Sentinel Diagnostics
• Eiken Chemical Co. Ltd
• BTNX Inc.
• R-Biopharm
• Other Prominent Players

Recent Industry Developments

Novel miRFec Screening Test Advances CRC Detection

In November 2022, researchers from Hospital Clínic-IDIBAPS and CIBER introduced miRFec, an innovative fecal screening test for colorectal cancer detection. A Japanese healthcare company initiated multicenter clinical research to evaluate the effectiveness of combining miRFec with FIT testing, potentially enhancing future cancer prevention strategies.

Sentinel Diagnostics Launches SENTiFIT 800 Analyzer

In June 2022, Sentinel Diagnostics unveiled the SENTiFIT 800 Analyzer, a high-throughput automated platform capable of processing up to one million FIT tests annually. The system is designed to reduce manual errors, improve laboratory efficiency, and support large-scale colorectal cancer screening programs.

About the Europe Fecal Immunochemical Test (FIT) Market

The Europe fecal immunochemical test market is experiencing robust growth driven by increasing colorectal cancer prevalence, expanding screening programs, growing preference for non-invasive diagnostics, and supportive healthcare policies. Continuous technological advancements in FIT analyzers and testing kits, combined with increasing public awareness of preventive healthcare, are expected to sustain market growth through 2034.